Coralville-based Viewpoint Molecular Targeting Inc., a radiopharmaceutical company developing precision alpha-particle oncology therapeutics and complementary diagnostic imaging agents, has announced it has launched patient enrollment and screening in a Phase 1 imaging study evaluating the company’s VMT01 program for the…